Ewan A. Gibb

Oct 7, 2023 | bjui-journals.onlinelibrary.wiley.com | Andrea Necchi |Giuseppe Basile |Ewan A. Gibb |Daniele Raggi

Supporting Information Filename Description bju16191-sup-0001-AppendixS1.xlsxExcel 2007 spreadsheet , 70.8 KB Appendix S1. Comparison of patient characteristics, genomic ancestry, pathogenic genomic alterations, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways between the VI-RADS categories. bju16191-sup-0002-FiguresS1-S5.pptxPowerPoint 2007 presentation , 4.5 MB Fig. S1. Flow chart displaying the patient selection and reasons for patients’ exclusion for the study.

Mar 16, 2023 | urotoday.com | Ewan A. Gibb

Ewan Gibb, a PhD scientist, discusses the Decipher Bladder clinical test, a molecular subtyping assay for bladder cancer that predicts the risk of upstaging, identifies high-risk neuroendocrine-like disease and determines the benefit from neoadjuvant chemotherapy. The test breaks a patient's tumor into one of five subtypes and recognizes luminal and non-luminal categories, with neuroendocrine being a smaller subset.